Accuray Inc ARAY
We take great care to ensure that the data presented and summarized in this overview for ACCURAY INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ARAY
View all-
Black Rock Inc. New York, NY8.23MShares$16.1 Million0.0% of portfolio
-
Neuberger Berman Group LLC New York, NY5.64MShares$11 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.35MShares$10.4 Million0.0% of portfolio
-
Heartland Advisors Inc Milwaukee, WI3.35MShares$6.54 Million0.32% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.79MShares$5.44 Million0.01% of portfolio
-
Foundry Partners, LLC2.19MShares$4.26 Million0.2% of portfolio
-
Geode Capital Management, LLC Boston, MA2.18MShares$4.25 Million0.0% of portfolio
-
State Street Corp Boston, MA1.89MShares$3.69 Million0.0% of portfolio
-
Royce & Associates LP1.88MShares$3.67 Million0.03% of portfolio
-
Harbert Fund Advisors, Inc. Birmingham, AL1.85MShares$3.61 Million1.97% of portfolio
Latest Institutional Activity in ARAY
Top Purchases
Top Sells
About ARAY
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
Insider Transactions at ARAY
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 02
2024
|
Suzanne C Winter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
119,698
-8.96%
|
$239,396
$2.15 P/Share
|
Dec 02
2024
|
Sandeep Chalke SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,749
-5.6%
|
$59,498
$2.15 P/Share
|
Dec 02
2024
|
Ali Pervaiz SVP Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,687
-6.83%
|
$53,374
$2.15 P/Share
|
Dec 02
2024
|
Jesse Chew Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
42,265
-11.45%
|
$84,530
$2.15 P/Share
|
Dec 02
2024
|
Michael Hoge Senior VP Global Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
24,675
-6.46%
|
$49,350
$2.15 P/Share
|
Nov 09
2024
|
Byron C Scott |
SELL
Payment of exercise price or tax liability
|
Direct |
22,642
-15.95%
|
$22,642
$1.98 P/Share
|
Nov 09
2024
|
Beverly A Huss |
SELL
Payment of exercise price or tax liability
|
Direct |
22,642
-10.78%
|
$22,642
$1.98 P/Share
|
Oct 29
2024
|
Ali Pervaiz SVP Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,207
-0.81%
|
$3,207
$1.86 P/Share
|
Sep 30
2024
|
Suzanne C Winter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,604
-1.23%
|
$16,604
$1.8 P/Share
|
Sep 30
2024
|
Jesse Chew Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,831
-3.36%
|
$12,831
$1.8 P/Share
|
Sep 30
2024
|
Michael Hoge Senior VP Global Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
8,102
-2.08%
|
$8,102
$1.8 P/Share
|
Sep 04
2024
|
Ali Pervaiz SVP Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,404
-2.09%
|
$16,808
$2.06 P/Share
|
Jun 30
2024
|
Suzanne C Winter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,731
-1.22%
|
$16,731
$1.76 P/Share
|
Jun 04
2024
|
Ali Pervaiz SVP Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,701
-0.67%
|
$2,701
$1.7 P/Share
|
May 29
2024
|
Joseph E Whitters |
BUY
Open market or private purchase
|
Direct |
50,000
+8.18%
|
$50,000
$1.58 P/Share
|
May 28
2024
|
Joseph E Whitters |
BUY
Open market or private purchase
|
Direct |
50,000
+8.91%
|
$50,000
$1.54 P/Share
|
Mar 01
2024
|
Michael Hoge Senior VP Global Operations |
SELL
Open market or private sale
|
Direct |
11,991
-2.98%
|
$23,982
$2.59 P/Share
|
Jan 03
2024
|
G Ina Corradetti VP, CAO and Controller |
SELL
Open market or private sale
|
Direct |
14,129
-6.72%
|
$28,258
$2.74 P/Share
|
Jan 03
2024
|
Ali Pervaiz SVP Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,116
-0.52%
|
$4,232
$2.74 P/Share
|
Dec 01
2023
|
Sandeep Chalke SVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
41,384
-3.68%
|
$82,768
$2.09 P/Share
|
Last 12 Months Summary
Open market or private purchase | 100K shares |
---|
Payment of exercise price or tax liability | 346K shares |
---|---|
Open market or private sale | 39.3K shares |